GUFICBIOBSEGufic Biosciences LtdMinimalNeutral
Announced Wed, 27 May · 16:22 IST

Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026 is attached herewith

GUFICBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+7.4%1-day move
₹323.15
prior close
₹328.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.0-2.2-2.2-2.6+7.4+9.2+12.0+9.0+15.2+19.0+9.6+19.3
Up moveDown movePending
AI summary

Gufic Biosciences Ltd has filed its Annual Secretarial Compliance Report for FY ended March 31, 2026, certified by Practicing Company Secretaries M/s Manish Ghia & Associates. The report confirms the company complied with all applicable SEBI regulations including LODR, ICDR, SAST, PIT, and Depositories regulations. All 11 compliance checkpoints including secretarial standards, board policies, website disclosures, director disqualification checks, and related party transactions were marked compliant. The only carryover matter from the previous year was a penalty of Rs 1,72,000 (excluding GST) imposed for appointing a director above 75 years without prior shareholder approval under Regulation 17(1A) – this was paid in March 2026 after BSE rejected the waiver application. NSE's waiver application remains pending.

Likely market impact

The clean compliance report is positive for investors as no regulatory violations or adverse observations were found. The resolved director appointment penalty indicates proactive regulatory management.